AI Terminal
Intercure Ltd.
Director's Dealing • Oct 12, 2021
6857_rns_2021-10-12_5b36c003-d94f-4d48-9659-c0bef390a929.pdf
Director's Dealing
Open in ViewerOpens in native device viewer
InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market
NEW YORK, TORONTO, and HERZLIYA, Israel – October 12, 2021 – InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company's common stock.
Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD\$7.03 per share (CAD \$8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD\$2,975,730 (CAD \$3,790,238 per share or NIS 9,608,631).
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
To be added to InterCure's email distribution list, please email [email protected] with "InterCure" in the subject.
Contact:
InterCure Ltd. Amos Cohen, Chief Financial Officer [email protected]
KCSA Strategic Communications Investor and Media Relations [email protected]
InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market
NEW YORK, TORONTO, and HERZLIYA, Israel – October 12, 2021 – InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company's common stock.
Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD\$7.03 per share (CAD \$8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD\$2,975,730 (CAD \$3,790,238 per share or NIS 9,608,631).
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
To be added to InterCure's email distribution list, please email [email protected] with "InterCure" in the subject.
Contact:
InterCure Ltd. Amos Cohen, Chief Financial Officer [email protected]
KCSA Strategic Communications Investor and Media Relations [email protected]